Androgen-independent Prostate Cancer: The Evolving Role of Chemotherapy

This publication has 63 references indexed in Scilit:

• Secondary myelodysplastic syndrome after treatment of prostate cancer with oral estramustine
  American Journal of Hematology, 2001
• THE USE OF BISPHOSPHONATE FOR THE PALLIATIVE TREATMENT OF PAINFUL BONE METASTASIS DUE TO HORMONE REFRACTORY PROSTATE CANCER
  Journal of Urology, 2001
• Simvastatin Promotes Osteoblast Differentiation and Mineralization in MC3T3-E1 Cells
  Biochemical and Biophysical Research Communications, 2001
• Biochemical Markers of Bone Turnover and Prediction of Hip Bone Loss in Older Women: The Study of Osteoporotic Fractures
  Journal of Bone and Mineral Research, 1999
• Effects of the Bisphosphonate Olpadronate in Patients With Carcinoma of the Prostate Metastatic to the Skeleton
  Bone, 1998
• Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the finnish prostate cancer group
  European Journal Of Cancer, 1993
• Evidence for a non-estrogenic cytostatic effect of estramustine on human prostatic carcinoma cells in vivo
  The Prostate, 1992
• Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells.
  The Journal of cell biology, 1988
• Nuclear protein matrix as a target for estramustine‐induced cell death
  The Prostate, 1986
• Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia
  Cancer, 1983